Protection of mice orally infected with Shiga toxin-producing Citrobacter rodentium treated with nanobody multimer

Clicks: 3
ID: 316085
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #129 of 208 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Shiga toxin (Stx) producing Escherichia coli (STEC) colonize the gut and cause enteritis through bacterial attachment-effacement (A/E) leading to mucosal damage. This facilitates systemic uptake of Stx which can often lead to hemolytic-uremic syndrome (HUS) and acute renal failure, particularly in children under 5 years of age. STEC infections expressing Stx2 variants are a major risk factor for HUS. Beyond patients receiving supportive care, there is no treatment for STEC-mediated HUS, and antibiotics are contraindicated. The 3–7-day prodromal interval between onset of STEC diarrhea and HUS offers a window for intervention for diarrheic patients, contacts thereof, or individuals exposed to the source of infection. Methods Citrobacter rodentium (Cr), a mouse pathogen which exhibits mucosal bacterial A/E, was genetically constructed to express Stx2d (Cr-Stx2d). This, along with a Cr parent strain carrying the kanamycin gene were used to model STEC in mice. Mice were treated intraperitoneally with a broad subtype-specific, Stx-neutralizing nanobody multimer fused to the human IgG1 Fc domain (VNA2-Stx/hFc). Results When a single treatment was administered as late as 4 days after Cr-Stx2d challenge, likely within the human STEC-HUS window of intervention, complete protection of mice was achieved. Conclusions This Cr-Stx2d model, which mimics elements of human STEC infections by causing mucosal gut lesions and systemic Stx2d mediated kidney damage, will help evaluate specific treatments against STEC-HUS, as demonstrated here with VNA2-Stx/hFc -treated mice given a single injection well after bacterial challenge. This product should be safe, simple and economical to manufacture.
Reference Key
openalex_W7163760473 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Abhineet Sheoran, Amanda J. Martinot, Sally R. Robinson, Anne Fu, Cara Martone, Denise Dayao, Charles B. Shoemaker, Saul Tzipori
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag357
URL
https://doi.org/10.1093/ofid/ofag357
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.